Enovis Corporation (ENOV)
Automate Your Wheel Strategy on ENOV
With Tiblio's Option Bot, you can configure your own wheel strategy including ENOV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ENOV
- Rev/Share 38.5543
- Book/Share 45.4458
- PB 0.6853
- Debt/Equity 0.5681
- CurrentRatio 2.2534
- ROIC -0.1799
- MktCap 1778241378.0
- FreeCF/Share -0.0696
- PFCF -449.9599
- PE -2.1352
- Debt/Assets 0.2917
- DivYield 0
- ROE -0.2985
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ENOV | JMP Securities | -- | Mkt Outperform | -- | $62 | Oct. 3, 2024 |
News
Wall Street Analysts Believe Enovis (ENOV) Could Rally 69.91%: Here's is How to Trade
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 69.9% upside potential for Enovis (ENOV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Enovis: Healthy Recon Trends Vs. Market Apathy
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Enovis remains out of favor despite solid results, but I still see potential for mid-single-digit revenue growth and low double-digit FCF margins long-term. The Recon business is performing well, gaining share in extremities, while P&R remains a slow-growth drag on overall performance and valuation. Tariff risks are manageable, but I'm unimpressed by the new CEO's lack of ortho experience.
Read More
Does Enovis (ENOV) Have the Potential to Rally 77.33% as Wall Street Analysts Expect?
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Enovis (ENOV) Q1 Earnings and Revenues Surpass Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Enovis (ENOV) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.50 per share a year ago.
Read More
Enovis Announces First Quarter 2025 Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12 th , 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Read More
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will feature its expanding portfolio of foot and ankle solutions at this year's American College of Foot & Ankle Surgeons (ACFAS) Annual Scientific Conference in Phoenix, Ariz., taking place March 27-30.
Read More
Enovis Corporation (ENOV) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Enovis Corporation (NYSE:ENOV ) Q4 2024 Results Conference Call February 26, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Berry - Senior VP & CFO Conference Call Participants Vic Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Jeff Johnson - Baird Brandon Vazquez - William Blair Danielle Antalffy - UBS Mike Matson - Needham & Company Caitlin Cronin - Canaccord Jason Wittes - ROTH Operator Good day, and welcome to the Enovis Fourth Quarter 2024 Earnings Conference Call. All participants will be …
Read More
Enovis Announces Fourth Quarter and Full Year 2024 Results
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Read More
Enovis Announces Planned CEO Succession Process
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors (the “Board”) of his intention to retire from his position as Chief Executive Officer (CEO) of Enovis, effective upon his successor being appointed by the Board and assuming the position as CEO. As part of the Company's succession planning process, the Board is actively working with an executive search firm to identify a growth-oriented MedTech leader who shares our passion for continuous improvement and patient outcomes, to …
Read More
About Enovis Corporation (ENOV)
- IPO Date 2008-05-08
- Website https://www.enovis.com
- Industry Industrial - Machinery
- CEO Damien McDonald
- Employees 7367